S Nagel1, C Busch, T Blankenburg, W Schütte. 1. Krankenhaus Martha-Maria, Halle-Dölau gGmbH, Klinik für Innere Medizin II, Halle. S.Nagel@MarthaMaria-Halle.de
Abstract
BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a known but rare disease, caused by human papilloma virus and characterised by multiple exophytic lesions and uncontrolled growth of papilloma in the respiratory tract. The most common complication of RRP is stenosis of the trachea. Medical therapeutic options have so far been less effective. However, inhibition of vascular endothelial growth factor (VEGF) by bevacizumab does appear to be an effective treatment option for RRP. CASE REPORT: The case of a 32-year-old male patient with RRP who has been treated for his symptomatic tracheal stenosis four times a year since 1996 is described. Only treatment by laser ablation showed any efficacy. Alternative treatment options did not show any effect. In May 2006 intrapulmonary lesions of RRP were also diagnosed but without any malignancy. From December 2007 to June 2008 the patient has been treated with bevacizumab. A visible regression of RRP and markedly less symptoms were observed. During this treatment no further laser ablation was necessary. CONCLUSION: Inhibition of VEGF by bevacizumab seems to offer a new and effective option in the medical management of RRP.
BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a known but rare disease, caused by human papilloma virus and characterised by multiple exophytic lesions and uncontrolled growth of papilloma in the respiratory tract. The most common complication of RRP is stenosis of the trachea. Medical therapeutic options have so far been less effective. However, inhibition of vascular endothelial growth factor (VEGF) by bevacizumab does appear to be an effective treatment option for RRP. CASE REPORT: The case of a 32-year-old male patient with RRP who has been treated for his symptomatic tracheal stenosis four times a year since 1996 is described. Only treatment by laser ablation showed any efficacy. Alternative treatment options did not show any effect. In May 2006 intrapulmonary lesions of RRP were also diagnosed but without any malignancy. From December 2007 to June 2008 the patient has been treated with bevacizumab. A visible regression of RRP and markedly less symptoms were observed. During this treatment no further laser ablation was necessary. CONCLUSION: Inhibition of VEGF by bevacizumab seems to offer a new and effective option in the medical management of RRP.
Authors: Douglas R Sidell; Karthik Balakrishnan; Simon R Best; Karen Zur; Julia Buckingham; Alessandro De Alarcon; Fuad M Baroody; Jonathan M Bock; Emily F Boss; Charles M Bower; Paolo Campisi; Sharon F Chen; Jeffrey M Clarke; Kevin D Clarke; Alejandro Cocciaglia; Robin T Cotton; Giselle Cuestas; Kara L Davis; Victor H DeFago; Frederik G Dikkers; Ines Dossans; Walter Florez; Elizabeth Fox; Aaron D Friedman; Nazaneen Grant; Osama Hamdi; Norman D Hogikyan; Kaalan Johnson; Liane B Johnson; Romaine F Johnson; Peggy Kelly; Adam M Klein; Claire M Lawlor; Nicolas Leboulanger; Alejandro G Levy; Derek Lam; Greg R Licameli; Steve Long; David G Lott; Dayse Manrique; James Scott McMurray; Kara D Meister; Anna H Messner; Michael Mohr; Pamela Mudd; Anthony J Mortelliti; Daniel Novakovic; Julian Ongkasuwan; Shazia Peer; Krysztof Piersiala; Jeremy D Prager; Seth M Pransky; Diego Preciado; Tiffany Raynor; Rico N P M Rinkel; Hugo Rodriguez; Verónica P Rodríguez; John Russell; María Laura Scatolini; Patrick Scheffler; David F Smith; Lee P Smith; Marshall E Smith; Richard J H Smith; Abraham Sorom; Amalia Steinberg; John A Stith; Dana Thompson; Jerome W Thompson; Patricio Varela; David R White; Andre M Wineland; Christina J Yang; Carlton J Zdanski; Craig S Derkay Journal: Laryngoscope Date: 2021-01-06 Impact factor: 2.970
Authors: Armando Bedoya; Kristen Glisinski; Jeffrey Clarke; Richard N Lind; Charles Edward Buckley; Scott Shofer Journal: Am J Case Rep Date: 2017-07-31
Authors: Michael Mohr; Christoph Schliemann; Christoph Biermann; Lars-Henning Schmidt; Torsten Kessler; Joachim Schmidt; Karsten Wiebe; Klaus-Michael Müller; Thomas K Hoffmann; Andreas H Groll; Claudius Werner; Christina Kessler; Rainer Wiewrodt; Claudia Rudack; Wolfgang E Berdel Journal: Oncol Lett Date: 2014-08-28 Impact factor: 2.967